- Open Access
Overcoming hypoxia-induced tumor radioresistance in non-small cell lung cancer by targeting DNA-dependent protein kinase in combination with carbon ion irradiation
Radiation Oncology volume 12, Article number: 208 (2017)
Hypoxia-induced radioresistance constitutes a major obstacle for a curative treatment of cancer. The aim of this study was to investigate effects of photon and carbon ion irradiation in combination with inhibitors of DNA-Damage Response (DDR) on tumor cell radiosensitivity under hypoxic conditions.
Human non-small cell lung cancer (NSCLC) models, A549 and H1437, were irradiated with dose series of photon and carbon ions under hypoxia (1% O2) vs. normoxic conditions (21% O2). Clonogenic survival was studied after dual combinations of radiotherapy with inhibitors of DNA-dependent Protein Kinase (DNAPKi, M3814) and ATM serine/threonine kinase (ATMi).
The OER at 30% survival for photon irradiation of A549 cells was 1.4. The maximal oxygen effect measured as survival ratio was 2.34 at 8 Gy photon irradiation of A549 cells. In contrast, no significant oxygen effect was found after carbon ion irradiation. Accordingly, the relative effect of 6 Gy carbon ions was determined as 3.8 under normoxia and. 4.11 under hypoxia. ATM and DNA-PK inhibitors dose dependently sensitized tumor cells for both radiation qualities. For 100 nM DNAPKi the survival ratio at 4 Gy more than doubled from 1.59 under normoxia to 3.3 under hypoxia revealing a strong radiosensitizing effect under hypoxic conditions. In contrast, this ratio only moderately increased after photon irradiation and ATMi under hypoxia. The most effective treatment was combined carbon ion irradiation and DNA damage repair inhibition.
Carbon ions efficiently eradicate hypoxic tumor cells. Both, ATMi and DNAPKi elicit radiosensitizing effects. DNAPKi preferentially sensitizes hypoxic cells to radiotherapy.
Tumor hypoxia is a critical factor contributing to acquired radioresistance and therapy failure [1, 2]. In line, tumor hypoxia was shown to correlate with poor prognosis and inferior therapeutic outcome in non-small cell lung cancer (NSCLC) [3, 4]. The lack of oxygen leads to decreased production of reactive oxygen species and consequently to reduced DNA damage after conventional radiotherapy with high energy photons [5, 6]. In vitro studies are usually conducted at relatively high oxygen concentrations (20%) compared to the physiological range of 3–7.4% detected in normal tissues . In tumor tissues, average oxygen levels are found to be even lower than 2%, hence referring to a hypoxic microenvironment . There is a relationship between decreased oxygen tension and gradual decline of radiation cell killing changing with different radiation qualities . However, relevant in vitro data on oxygen enhancement ratio (OER) measurements are sparse  but urgently needed to adjust treatment planning with more faithful oxygen concentrations and to evaluate the impact of different radiation qualities and multimodal treatments.
Induction of DNA damage is a hallmark of radiation induced cell toxicity . The relevant, lethal DNA damage, complex double-strand breaks (DSB), are repaired by two major pathways, i.e., homologous recombination and non-homologous end-joining. For each of these pathways, members of the phosphotidylinositol-3-kinase (PIK) family are recruited to DSBs: Ataxia-telangiectasia mutated (ATM) and DNA-dependent protein kinase with its catalytic subunit (DNA-PKc). Inhibitors of these key players in DNA damage response (DDR) pathways were shown to enhance the efficacy of radiotherapy . In contrast to sparsely ionizing photon radiation, carbon ions are densely ionizing along their traversal and are considered high linear energy transfer (LET) irradiation . The application of high-LET beams has been shown to increase tumor cell killing by inducing more complex DNA damage that results in an increased radiobiological effectiveness (RBE) . It has been further reported that cell killing by high-LET radiation might be less dependent on the tumor oxygen status [9, 15].
In this study, the effect of carbon ions vs. conventional photon irradiation was investigated on two NSCLC cell lines. We report on the radiosensitizing effect of two novel DDR inhibitors, DNAPKi and ATMi, with photon- and carbon ion irradiation under hypoxic conditions.
The US National Cancer Institute (NCI) offers a panel of 60 human tumor cell lines (NCI-60 panel, https://dtp.cancer.gov/discovery_development/nci-60/) for in vitro evaluations including anti-cancer compounds . From this panel, the NSCLC cell lines A549 and NCI-H1437 (H1437) cells were purchased from the American Type Culture Collection (ATCC). Cells were grown in RPMI 1640 Medium (Gibco) supplemented with 10% Fetal Bovine Serum (FBS) at 37 °C and 5% CO2 atmosphere. Experiments in hypoxic conditions were performed at 1% O2 and 5% CO2.
To assess clonogenic survival under hypoxic conditions, we devised a system to irradiate cells in 96-well plates while incubated in a hypoxia chamber (C-chamber; Biospherix) allowing online monitoring of CO2 and O2 concentrations (ProOx and ProCO2 model; Biospherix) during the entire experiment (Fig. 1a). 50, 100 or 200 A549 cells/well and 100, 200 or 300 H1437 cells /well were seeded up to 16 h before irradiation. Cell numbers increased with escalation of dose and drug concentration. Inhibitors were added to the cells at 50 nM, 100 nM, 200 nM, 500 nM, or 1000 nM for normoxia and at 100 nM, 200 nM, or 500 nM for hypoxia and at 100 nM for carbon ion irradiation. Both ATM and DNA-PK inhibitors were dissolved in DMSO and diluted in RPMI 1640 medium. Controls also contained <0.1% DMSO. To determine the effect of drug treatment alone on clonogenic survival (Plating efficiency, PE), dose series of both compounds at 0, 50, 100, 200, 500, and 1000 nM were analyzed without irradiation. After exposure to inhibitors, cells were incubated for 4 h in hypoxia or in normoxia, respectively. For photon radiation, a vertical beam direction was used to irradiate plates at four different doses. For horizontal carbon ion beams, an irradiation plan was developed to deliver four different doses in SOBP region of the beam.
Cells were irradiated in the hypoxia chamber with a dose series of photons (1, 2, 4, or 8 Gy) and carbon ions (approx. 1, 2, 4, or 6 Gy) and thereafter incubated under normoxic conditions. Inhibitors were left in the media for 24 h and then replaced with fresh RPMI 1640 medium and the plates were returned to the incubator for colony formation. After 4 (A549) or 7 days (H1437) plates were imaged by microscopy at 4× magnification (IncuCyte, Essen Bioscience). The images were analyzed by the IncuCyte Zoom Software (Essen Bioscience) and colony counts were confirmed by manual curation. Counts were normalized to non-irradiated samples at each corresponding baseline inhibitor concentration.
Dose planning and simulations
Photon planning was done with Raystation treatment planning system (RaySearch Laboratories) based on a CT scan of the hypoxia chamber containing 96-well plates filled with water. Irradiation was performed on a Siemens Artiste (6 MV). For carbon ion delivery, Spread-out Bragg peak (SOBP) was physically optimized with the Treatment Planning for Particles (TRiP98) system, using a 30x30x30 cm3 water phantom positioned at 100 cm source-surface distance (SSD) . To reduce physical uncertainties on cell survival introduced by the heterogeneous target, a detailed geometry of the utilized 96-well plates was incorporated into a FLUKA Monte Carlo simulation of the Heidelberg Ion Beam Therapy (HIT) beam-line . Dose maps were generated, with dose uniformity found to be within 2% range in the SOBP region. Carbon dose levels for planned 1, 2, 4 and 6 Gy were corrected accordingly to actual prescribed 0.95, 1.9, 3.8, and 5.64 Gy.
Software and calculations
The survival fractions derived from the clonogenic survival data were fitted according to the linear-quadratic model for photons. A linear model was applied to carbon ion data. The fits as well as OER, RBE, and SER values (Additional file 1: Table S5 and Table S6) were calculated using an in-house tool based on Minuit package available in ROOT . PE values were plotted with GraphPad Prism 5. To display the oxygen effect, the relative effect of carbon ions, and the sensitization effect of inhibitors, measured data points were used to determine ratios of clonogenic survival at a corresponding dose: Ratios were calculated as survival fractions of hypoxic cells and normoxic cells; survival fractions of cells irradiated with photons and cells irradiated with carbon ions; survival fractions of mock-treated cells and cells treated with inhibitors at the same dose, respectively. Effects were compared at a preferential dose of 4 Gy being a reasonable dose for patients in fractionated therapy.
Data are presented as means and standard deviations (SD). Statistical significance was determined using unpaired t-test (two-tailed). The asterisks represent significantly different values. Data represent average values of at least three independent experiments, each performed with technical quadruplicates (n:4).
Oxygen effect and relative effect for photon vs. carbon irradiation under hypoxia
Hypoxia increased the survival fraction of A549 cells significantly (between 1.36 to 2.34-fold) at photon doses ≥4 Gy under hypoxia vs. normoxia (p < 0.05). In contrast, no significant oxygen effect was found after carbon ion irradiation (Fig. 1b, Table 1). The calculated OER at 30% survival was 1.4 for photons and 1.2 for carbon ions (Additional file 1: Table S5A). Accordingly, the survival ratios displaying the relative effect of carbon ion vs. photon irradiation at 4 Gy increased from 3.8 under normoxia to 4.11 at 1% O2 concentration (Table 2). Corresponding RBE values calculated from fits at 30% survival are 2.7 under normoxia and 3.1 under hypoxia. The survival data for H1437 cells are presented in the supplemental material.
Preferential Radiosensitization of hypoxic cells to DNAPKi
Next, we investigated the inherent and radiosensitizing effect of two novel DNAPK and ATM serine-threonine kinase inhibitors. The PE was not significantly reduced after ATMi treatment. The PE was only significantly reduced by 15% after 1000 nM of DNAPKi (Fig. 2). This is in line with the reported high selectivity and on target potency of these compounds: DNAPKi (M3814) is a highly potent and selective inhibitor of DNA-PK with subnanomolar potency on its target [20, 21]. The split to closely related PIKK proteins has been measured in biochemical assays and is about 150-fold to PI3K delta and greater than 400-fold to the other family members (ATM, PI3Kalpha – delta, mTOR). The preclinical ATM inhibitor tested is a subnanomolar potent inhibitor with 50-fold selectivity over DNA-PK and greater than 1000-fold selectivity against the other PIKK family members (ATR, PI3Kalpha – delta, mTOR).
After photon irradiation both compounds exhibited dose dependent radiosensitizing effects under normoxic and hypoxic conditions (Fig. 3). For 100 nM ATMi, the sensitization effect at 4 Gy photons increased from 1.4 under normoxia to 1.6 under hypoxia (Table 3). The radiosensitizing effect of DNAPKi was markedly enhanced under hypoxic conditions. For 100 nM DNAPKi the survival ratio at 4 Gy more than doubled from 1.5 under normoxia to 3.3 under hypoxia (Fig. 3, Table 3). The enhanced sensitizing effect of DNAPKi under hypoxia was found in both cell lines (Additional file 1: Fig. S3).
Effect of DDR inhibition in combination with carbon ion irradiation
Next, we aimed to discover the potential of DDR inhibitors to further improve eradication of radioresistant hypoxic cells. Based on the PE data demonstrating no relevant cytotoxicity at 100 nM for both inhibitors (Fig. 2), but strong radiosensitizing effects after photon irradiation (Fig. 3), this concentration was selected for combinations with carbon ion irradiation. Both inhibitors exhibit potent radiosensitizing effects in combination with high-LET carbon irradiation (Fig. 4). The SER at 30% survival was 1.5 for 100 nM ATMi and carbon irradiation under normoxic conditions (Additional file 1: Table S5B). This radiosensitizing effect was not further enhanced by addition of ATMi to carbon ions under hypoxic condition. In contrast, the SER at 30% survival increased from 1.7 under normoxia to 1.9 under hypoxia after combined carbon irradiation and DNAPKi. When comparing survival ratios after treatment with DNAPKi and 4 Gy carbon ion irradiation the ratios increased from 3.4 to 5.1 normoxia vs. hypoxia (Table 4). Overall, combination of DNAPKi and carbon irradiation most efficiently eradicated hypoxic NSCLC tumor cells.
We report here efficient eradication of hypoxic NSCLC tumor cells, in particular, after combined DNAPKi and ionizing radiation. Both, ATMi and DNAPKi demonstrated a gradual dose dependent radiosensitizing effect under normoxia and hypoxic conditions. Our data further confirmed findings from previous work reporting on a minimal dependency of high-LET carbon beams on cellular oxygen concentration [22, 23]. A combination of DNAPKi and carbon ions most efficiently eradicated hypoxic tumor cells (Fig. 4b).
To investigate irradiation effects under hypoxic conditions, establishing an in vitro experimental approach closest to the in vivo situation was a prerequisite. Current systems for conducting radiation experiments under hypoxic conditions may show some limitations e.g., utilize a strict anoxic environment that may not reflect the moderate hypoxic niche of the radioresistant tumor cell populations [24, 25]. We devised a system that allows to work with standard cell culture plates and conveniently transfer them between normoxia and different online monitored hypoxic conditions such as the 1% O2 utilized in this study. Moreover, the high-throughput performance in 96-well format with cell lines that form circumscribed colonies outperforms currently existing petri dish-sized hypoxia systems . With this option, we were able to combine potential radiosensitizers with irradiation in an identical setting under normoxia and hypoxia.
ATM and DNA-PKc are two central constituents of DDR and their inhibition was shown to radiosensitize NSCLC cell lines [27, 28] as well as other tumor entities [29, 30] to photon irradiation under normoxia. However, only little is known about the effect of DNA-PKc inhibition on the radiosensitivity of hypoxic cells. Lindquist and colleagues described radiosensitivity effects with photon irradiation of DNA-PK deficient mouse embryonic fibroblast cells (SCID/st) under normoxic and hypoxic conditions compared to isogenic DNA-PK wildtype cells (CB.17) and that DNA-PK inhibition in combination with photon irradiation decreases the clonogenic survival of both oxic and hypoxic cells . They suggested that impairment of DNA-PK radiosensitizes independently of cellular oxygen status. In contrast, we found a marked enhancement of DNAPKi radiosensitizing effects under hypoxia, in both cell lines, but not for ATM inhibition. One plausible explanation for this phenomenon is that moderate hypoxia may alter DNA repair signaling e.g., by post-translational modifications in a HIF-dependent manner . Our data suggest that the therapeutic window for DNAPKi might be broader than originally anticipated by efficient eradication of the most radioresistant cells residing in the hypoxic tumor niche. This hypothesis, once successfully confirmed by in vivo experiments, could form the basis for rationally designed clinical trials investigating the impact of DNAPKi in otherwise radioresistant hypoxic tumors.
In addition to pharmacological radiosensitization of hypoxic cells, we provide here novel rationale to combine DDR inhibitors with high-LET carbon ion irradiation. The high RBE of carbon ions is attributed to their ability to form more complex unrepairable DSB correlating with large nuclear repair foci and increased number of residual DNA damage [14, 33]. Our results with NSCLC cell lines confirm data for CHO-K1 cells  showing that the low dependency of high-LET irradiation on cellular oxygen would further increase the RBE under hypoxic conditions. Additionally, these findings justify the usage of carbon ions to treat patients with hypoxia-associated radioresistant tumors.
We further evaluated the significance of inhibiting DDR with carbon ions. Interestingly, the sensitizing effect of DNAPKi was more pronounced than the effect of ATM inhibition. Moreover, the DNAPKi sensitizing effect was substantially enhanced (between ~50–60%) in survival ratios after carbon irradiation under hypoxic compared to normoxic conditions. On the contrary, the ATMi sensitizing effect remained in the same range under hypoxic vs. normoxic conditions after carbon ion irradiation. It is conceivable that the formation of lethal complex DNA damages is enhanced with higher photon doses, higher LET and inhibition of DNA-PKc. However, further mechanistic studies are needed to dissect the molecular mechanisms underlying the superior radiosensitizing principle behind DNAPKi treatment under hypoxic conditions.
Dual therapy with DNAPKi and carbon ion irradiation demonstrated the highest efficacy in eradicating otherwise radioresistant hypoxic tumors. Our data suggest potent reversal of the radioresistant phenotype of hypoxic tumors by DNAPKi that warrants further preclinical and clinical evaluation.
Inhibitor of ATM
DNA damage response
Catalytic subunit of DNA-dependent Protein Kinase
Inhibitor of DNA-dependent Protein Kinase
Linear energy transfer
Non-small cell lung cancer
Oxygen enhancement ratio
Relative biological effect
Reactive oxygen species
Sensitization enhancement ratio
Spread-out Bragg peak
Overgaard J. Hypoxic radiosensitization: adored and ignored. J Clin Oncol. 2007;25(26):4066–74.
Tawk B, Schwager C, Deffaa O, et al. Comparative analysis of transcriptomics based hypoxia signatures in head- and neck squamous cell carcinoma. Radiother Oncol. 2016;118(2):350–8.
Vera P, Thureau S, Chaumet-Riffaud P, et al. Phase II study of a radiotherapy total dose increase in hypoxic lesions identified by 18F-misonidazole PET/CT in patients with non–small cell lung carcinoma (RTEP5 study). J Nucl Med. 2017;58:1045–53.
Eschmann SM, Paulsen F, Reimold M, et al. Prognostic impact of hypoxia imaging with 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy. J Nucl Med. 2005;46:253–60.
Quintiliani M. The oxygen effect in radiation inactivation of DNA and enzymes. Int J Radiat Biol Relat Stud Phys Chem Med. 1986;50(4):573–94.
Ward JF. DNA damage produced by ionizing radiation in mammalian cells: identities, mechanisms of formation, and reparability. Prog Nucleic Acid Res Mol Biol. 1988;35:95–125.
Gray LH, Conger AD, Ebert M, Hornsey S, OCA S. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol. 1953;26(312):638–48.
McKeown SR. Defining normoxia, physoxia and hypoxia in tumors - implications for treatment response. Br J Radiol. 2014;87(1035):20130676.
Antonovic L, Brahme A, Furusawa Y, Toma-Dasu I. Radiobiological description of the LET dependence of the cell survival of oxic and anoxic cells irradiated by carbon ions. J Radiat Res. 2013;54(1):18–26.
Scifoni E, Tinganelli W, Kraft-Weyrather W, et al. Including oxygen enhancement ratio in ion beam treatment planning: model implementation and experimental verification. Phys Med Biol. 2013;58(11):3871.
Toulany M, Rodemann HP. Phosphatidylinositol 3-kinase/Akt signaling as a key mediator of tumor cell responsiveness to radiation. Semin Cancer Biol. 2015;35:180–90.
Darzynkiewicz Z, Traganos F, Wlodkowic D. Impaired DNA damage response--an Achilles’ heel sensitizing cancer to chemotherapy and radiotherapy. Eur J Pharmacol 2009;625(1–3):143–50.
Curtis SB. Calculated LET distributions of heavy ion beams. Int J Radiat Oncol Biol Phys. 1977;3:87–91.
Dokic I, Mairani A, Niklas M, et al. Next generation multi-scale biophysical characterization of high precision cancer particle radiotherapy using clinical proton, helium-, carbon- and oxygen ion beams. Oncotarget. 2016;7(35):56676–89.
Wenzl T, Wilkens JJ. Modelling of the oxygen enhancement ratio for ion beam radiation therapy. Phys Med Biol. 2011;56(11):3251–68.
Wang H, Huang S, Shou J, et al. Comparative analysis and integrative classification of NCI60 cell lines and primary tumors using gene expression profiling data. BMC Genomics. 2006;7:166.
Krämer M, Jäkel O, Haberer T, Kraft G, Schardt D, Weber U. Treatment planning for heavy-ion radiotherapy: physical beam model and dose optimization. Phys Med Biol. 2000;45(11):3299–317.
Tessonnier T, Marcelos T, Mairani A, et al. Phase space generation for proton and carbon ion beams for external Users' applications at the Heidelberg ion therapy Center. Front Oncol. 2016;5:297.
Brun R, Rademakers F. ROOT — an object oriented data analysis framework. Nuclear Instruments and Methods in Physics Research Section A: Accelerators, Spectrometers, Detectors and Associated Equipment. 1997;389(1–2):81–6.
Damstrup L, Zimmerman A, Sirrenberg C, Zenke FT, Vassilev L. M3814, a DNA-dependent protein Kinase inhibitor (DNA-PKi), potentiates the effect of ionizing radiation (IR) in Xenotransplanted Tumors in nude mice. Int J Rad Onc. 2016;94(4):940–1.
Zenke FT, Zimmermann A, Sirrenberg C et al. Abstract 1658: M3814, a novel investigational DNA-PK inhibitor: enhancing the effect of fractionated radiotherapy leading to complete regression of tumors in mice. July 2016 Proceedings: AACR 107th Annual Meeting 2016;16–20, 2016; New Orleans, LA.
Bopp C, Hirayama R, Inaniwa T, et al. Adaptation of the microdosimetric kinetic model to hypoxia. Phys Med Biol. 2016;61(21):7586–99.
Tinganelli W, Durante M, Hirayama R, et al. Kill-painting of hypoxic tumours in charged particle therapy. Scientific Reports. 2015;5:17016.
Wouters BG, Brown JM. Cells at intermediate oxygen levels can be more important than the ‘hypoxic fraction’ in determining tumor response to fractionated radiotherapy. Radiat Res. 1997;147(5):541.
Bussink J, Kaanders JHAM, van der Kogel AJ. Tumor hypoxia at the micro-regional level: clinical relevance and predictive value of exogenous and endogenous hypoxic cell markers. Radiother Oncol. 2003;67(1):3–15.
Tinganelli W, Ma N-Y, Von Neubeck C, et al. Influence of acute hypoxia and radiation quality on cell survival. J Radiat Res. 2013;54(suppl 1):i23–30.
Toulany M, Mihatsch J, Holler M, Chaachouay H, Rodemann HP. Cisplatin-mediated radiosensitization of non-small cell lung cancer cells is stimulated by ATM inhibition. Radiother Oncol. 2014;111(2):228–36.
Sunada S, Kanai H, Lee Y, et al. Nontoxic concentration of DNA-PK inhibitor NU7441 radio-sensitizes lung tumor cells with little effect on double strand break repair. Cancer Sci. 2016;107(9):1250–5.
Batey MA, Zhao Y, Kyle S, et al. Preclinical evaluation of a novel ATM inhibitor, KU59403, in vitro and in vivo in p53 functional and dysfunctional models of human cancer. Mol Cancer Ther. 2013;12(6):959–67.
Ciszewski WM, Tavecchio M, Dastych J, Curtin NJ. DNA-PK inhibition by NU7441 sensitizes breast cancer cells to ionizing radiation and doxorubicin. Breast Cancer Res Treat. 2014;143(1):47–55.
Lindquist KE, Cran JD, Kordic K, et al. Selective radiosensitization of hypoxic cells using BCCA621C: a novel hypoxia activated prodrug targeting DNA-dependent protein kinase. Tumor Microenvironment and Therapy. 2013;03:46–55.
Scanlon SE, Glazer PM. Multifaceted control of DNA repair pathways by the hypoxic tumor microenvironment. DNA Repair. 2015;32:180–9.
Sørensen BS, Horsman MR, Alsner J, et al. Relative biological effectiveness of carbon ions for tumor control, acute skin damage and late radiation-induced fibrosis in a mouse model. Acta Oncol. 2015;54(9):1623–30.
This study was conducted in the frame of German Research Foundation (DFG) “clinical research group heavy ion therapy (KFO-214)” within the project TP5 “Heavy Ions in Lung Cancer”. Both ATM and DNA-PK inhibitors were kindly provided by Merck (Darmstadt). The authors would like to thank Claudia Rittmüller, Nora Schuhmacher, and Christiane Rutenberg for their excellent technical assistance.
This work was supported by German Research Foundation (DFG-KFO214, TP5), It was also in part funded by Deutsche Krebshilfe (Max-Eder 108,876) and intramural funds from National Center for Tumor diseases (NCT3.0_2015.21/22 NCT-PRO and Biodose programs). The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.
Availability of data and materials
Data generated or analyzed during this study are included in this published article (and its supplementary information files).
Ethics approval and consent to participate
Consent for publication
Astrid Zimmerman, Frank Zenke and Andree Blaukat are Merck employee. Amir Abdollahi and Jürgen Debus received research funds from Merck and are involved as academic mentors in the DNA-Repair Cluster initiative with Merck-BioMedX. Other authors declare no conflict of interest.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Additional file 1:
S1-S4 Clonogenic survival of H1437 cells; In parallel to A549, another NSCLC cell line, H1437, was used in the same setup to compare the oxygen effect as well as sensitizing effects of inhibitors with photon vs. carbon ion irradiations. S5 Table listing OER, RBE, and SER for A549 and H1437 cells. OER, RBE, and SER were calculated from linear quadratic fits at 30% survival. (PDF 524 kb)
Rights and permissions
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
About this article
Cite this article
Klein, C., Dokic, I., Mairani, A. et al. Overcoming hypoxia-induced tumor radioresistance in non-small cell lung cancer by targeting DNA-dependent protein kinase in combination with carbon ion irradiation. Radiat Oncol 12, 208 (2017). https://doi.org/10.1186/s13014-017-0939-0
- Lung cancer
- Serine/threonine kinase inhibitors
- Carbon ions